Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. It also identifies novel targets and develops new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need. The company was founded by Alan Ashworth, William G. Kaelin, Jr., Jose Baselga, and Antoni Ribas in 2017 and is headquartered in Boston, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
MVA Investors, LLC | | Jun 07 '24 | Sale | 6.88 | 77,000 | 529,760 | 343,524 | Jun 07 09:14 PM | MVA Investors, LLC | | Jun 06 '24 | Sale | 7.24 | 63,000 | 456,120 | 420,524 | Jun 07 09:14 PM | MVA Investors, LLC | | May 03 '24 | Sale | 7.61 | 60,000 | 456,600 | 483,524 | May 03 09:34 PM | MVA Investors, LLC | | May 02 '24 | Sale | 7.56 | 75,000 | 567,000 | 543,524 | May 03 09:34 PM | MVA Investors, LLC | | May 01 '24 | Sale | 7.43 | 75,000 | 557,250 | 618,524 | May 03 09:34 PM | Third Rock Ventures IV, L.P. | 10% Owner | Feb 20 '24 | Sale | 12.00 | 162,500 | 1,950,000 | 19,201,475 | Feb 21 05:52 PM | Weber Barbara | Chief Executive Officer | Feb 07 '24 | Sale | 12.62 | 4,457 | 56,246 | 1,535,167 | Feb 08 09:14 PM | Crystal Adam | See Remarks | Feb 07 '24 | Sale | 12.62 | 4,083 | 51,527 | 119,478 | Feb 08 09:04 PM | Beckman Daniella | Chief Financial Officer | Feb 07 '24 | Sale | 12.62 | 1,817 | 22,930 | 132,397 | Feb 08 09:08 PM | Barry Douglas | General Counsel | Feb 07 '24 | Sale | 12.62 | 1,354 | 17,087 | 43,981 | Feb 08 09:09 PM | Weber Barbara | Chief Executive Officer | Feb 06 '24 | Sale | 12.56 | 4,681 | 58,806 | 1,539,624 | Feb 08 09:14 PM | Crystal Adam | See Remarks | Feb 06 '24 | Sale | 12.56 | 4,288 | 53,868 | 123,561 | Feb 08 09:04 PM | Beckman Daniella | Chief Financial Officer | Feb 06 '24 | Sale | 12.56 | 1,908 | 23,969 | 134,214 | Feb 08 09:08 PM | Barry Douglas | General Counsel | Feb 06 '24 | Sale | 12.56 | 1,422 | 17,864 | 45,335 | Feb 08 09:09 PM | Crystal Adam | See Remarks | Nov 01 '23 | Sale | 8.39 | 7,507 | 62,994 | 81,250 | Nov 02 04:49 PM | Boxer Capital, LLC | | Oct 16 '23 | Buy | 6.84 | 500,000 | 3,420,000 | 8,198,642 | Oct 17 06:04 PM | Boxer Capital, LLC | | Oct 13 '23 | Buy | 7.07 | 750,000 | 5,302,500 | 7,698,642 | Oct 17 06:04 PM | Boxer Capital, LLC | | Oct 09 '23 | Sale | 9.97 | 175,000 | 1,744,750 | 6,948,642 | Oct 11 09:22 PM | Boxer Capital, LLC | | Oct 09 '23 | Sale | 9.91 | 50,000 | 495,500 | 693,524 | Oct 11 09:22 PM | Boxer Capital, LLC | | Aug 11 '23 | Buy | 5.15 | 475,000 | 2,446,250 | 743,542 | Aug 15 09:34 PM |
|